DOSING REGIMEN OF ROVATIRELIN FOR ATAXIA ASSOCIATED WITH SPINOCEREBELLAR DEGENERATION

The present invention is directed to provide excellent pharmaceutical compositions for the treatment of ataxia in spinocerebellar degeneration with which the risk of side effects caused by elevation of thyroid hormone levels is reduced. The present invention relates to a pharmaceutical composition f...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	KIYONO, Yuji, YAMANO, Hitoshi, SHIMIZU, Yoshitaka, IJIRO, Tomoyuki
Format:	Patent
Sprache:	eng ; fre ; ger
Schlagworte:	HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention is directed to provide excellent pharmaceutical compositions for the treatment of ataxia in spinocerebellar degeneration with which the risk of side effects caused by elevation of thyroid hormone levels is reduced. The present invention relates to a pharmaceutical composition for treatment of ataxia in spinocerebellar degeneration including, as an active ingredient, a daily dose of 1.6 mg to 3.2 mg of rovatirelin or 1.6 mg to 3.2 mg of pharmacologically acceptable salt of rovatirelin as being calculated as a free form, wherein the pharmaceutical composition is administered once daily. The pharmaceutical compositions of the present invention are particularly useful as therapeutic agents for ataxia in SCD.